Skip to main content

University of Basel and RocketVax present new Covid vaccine

| News

University of Basel and RocketVax present new Covid vaccine


Researchers from the University of Basel have developed a new concept for a Covid vaccine in collaboration with the biotech startup RocketVax. It is based on a modified version of the virus that can no longer replicate. The vaccine can be produced cost-effectively and is simple to store and administer.

Covid vaccine research in the laboratory (image: University of Basel)

The University of Basel and RocketVax, a biotechnology startup also based in Basel, are focusing on a new principle, namely single-cycle viruses, in the development of a new vaccine. According to a press release, the vaccine can simply be stored in a refrigerator. It is administered by nasal drop, which does not require trained medical personnel. In addition, the production method for the vaccine is said to be particularly cost-effective and can be easily adapted to future virus variants.

The vaccine is based on a modified version of the coronavirus produced in a lab setting. However, it is unable to replicate further after entering the human body. “Among other things, we remove a specific gene from the blueprint for the viral envelope”, as study leader Prof. Dr. Thomas Klimkait from the Department of Biomedicine at the University of Basel explains in the press release, adding that: “If this envelope component is missing, no new virus particles can be formed”.

Broad financial support

However, the individual virus components are still produced. The body cells present these on their surface to the immune system, which recognizes the virus building blocks and builds up effective immune protection. The team also removed genes that the virus uses to inhibit the immune response of the cells. A patent application for the concept has now also been submitted by the researchers.

RocketVax collaborated on the development and preclinical studies. For the successful animal experiments with hamsters, the team cooperated with the Friedrich Loeffler Institute in Germany. The partnership is embedded in a research cooperation with University Hospital of Basel and the Swiss Tropical and Public Health Institute (Swiss TPH). The University Hospital of Basel and the Canton of Basel-Stadt provided startup funding for the preclinical research activities in connection with the new vaccine, which were already underway. The project also received financial support from Innosuisse, the Swiss innovation agency.

Share this article

Sign up to receive our newsletter in your inbox.

You may also be interested in

Nouscom secures 67.5 million euros in financing

Biotech company Nouscom has raised 67.5 million euros in a series C financing round. The Basel-based firm intends to use...
Read More

Celebrating six months of innovation: i4Challenge accelerator New Ideas 2022/2023

On the 5th of July 2023, the 3rd iteration of the i4Challenge accelerator program New Ideas came to its conclusion....
Read More

How open innovation in healthtech hubs is fueling the rise of digital healthcare

How the ever-increasing uptake of digital solutions is enhancing patient engagement, increasing access to care and lowering the cost of...
Read More

Paradigm shift in pain management

Pain is a crucial sensation for survival, but it can also drive us to depression and long-term suffering if not...
Read More

BOOM Summit in Basel accelerates health technology

The BOOM Summit at Messe Basel in April 2024 will be a completely new kind of healthcare conference. The first...
Read More

Investors stump up 3.7 million Swiss francs in Onena Medicines

Onena Medicines has secured an investment of 3.7 million Swiss francs. The portfolio company of the biotech startup incubator BaseLaunch...
Read More

Do you have a question? We'd like to hear from you.